Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome

[1]  Lynn A. Hyde,et al.  Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination , 2011, Pharmacology Biochemistry and Behavior.

[2]  Richard Paylor,et al.  Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic‐like responses , 2011, Autism research : official journal of the International Society for Autism Research.

[3]  S. Maehara,et al.  Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice. , 2010, European Journal of Pharmacology.

[4]  M. Bear,et al.  Mechanism-based approaches to treating fragile X. , 2010, Pharmacology & therapeutics.

[5]  R. Kooy,et al.  Fragile X syndrome: from molecular genetics to therapy , 2009, Journal of Medical Genetics.

[6]  R. Paylor,et al.  Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety , 2009, Psychopharmacology.

[7]  Randi J. Hagerman,et al.  Advances in the Treatment of Fragile X Syndrome , 2009, Pediatrics.

[8]  M. Geyer,et al.  Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice , 2009, Neurotoxicity Research.

[9]  D. Nelson,et al.  Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene. , 2008, Behavioral neuroscience.

[10]  Chris I. De Zeeuw,et al.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice , 2008, Neurobiology of Disease.

[11]  A. Reiss,et al.  Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. , 2008, American journal of mental retardation : AJMR.

[12]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[13]  Christina Gross,et al.  Dysregulated Metabotropic Glutamate Receptor-Dependent Translation of AMPA Receptor and Postsynaptic Density-95 mRNAs at Synapses in a Mouse Model of Fragile X Syndrome , 2007, The Journal of Neuroscience.

[14]  Liang Li,et al.  Metabotropic glutamate subtype 5 receptors modulate fear-conditioning induced enhancement of prepulse inhibition in rats , 2007, Neuropharmacology.

[15]  Michael Lardelli,et al.  Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. , 2006, Human molecular genetics.

[16]  G. Fox,et al.  Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A‐841720, a novel non‐competitive mGluR1 receptor antagonist , 2006, British journal of pharmacology.

[17]  S. Ferguson,et al.  Associate editor: P. Molenaar , 2022 .

[18]  J. Millán.  Knockout Mouse Models , 2006 .

[19]  L. Volk,et al.  Differential roles for group 1 mGluR subtypes in induction and expression of chemically induced hippocampal long-term depression. , 2006, Journal of neurophysiology.

[20]  K. Hsu,et al.  Sustained activation of metabotropic glutamate receptor 5 and protein tyrosine phosphatases mediate the expression of (S)‐3,5‐dihydroxyphenylglycine‐induced long‐term depression in the hippocampal CA1 region , 2006, Journal of neurochemistry.

[21]  M. Tranfaglia,et al.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.

[22]  P. Jeffrey Conn,et al.  Metabotropic glutamate receptors in the basal ganglia motor circuit , 2005, Nature Reviews Neuroscience.

[23]  E. De Schutter,et al.  Deletion of FMR1 in Purkinje Cells Enhances Parallel Fiber LTD, Enlarges Spines, and Attenuates Cerebellar Eyelid Conditioning in Fragile X Syndrome , 2005, Neuron.

[24]  W. Danysz,et al.  mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition , 2005, Neuropharmacology.

[25]  Yan Wang,et al.  Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome , 2005, Neuron.

[26]  R. Bertorelli,et al.  The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles , 2005, Psychopharmacology.

[27]  X. Langlois,et al.  JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist , 2004, Neuropharmacology.

[28]  R. E. Brown,et al.  A phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse , 2004, Genes, brain, and behavior.

[29]  N. Cosford,et al.  The Behavioral Profile of the Potent and Selective mGlu5 Receptor Antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in Rodent Models of Anxiety , 2004, Neuropsychopharmacology.

[30]  J. Schiefer,et al.  The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.

[31]  Eric Klann,et al.  Activation of the Phosphoinositide 3-kinase–akt–mammalian Target of Rapamycin Signaling Pathway Is Required for Metabotropic Glutamate Receptor-dependent Long-term Depression , 2022 .

[32]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[33]  Alcino J. Silva,et al.  Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice , 2004, Molecular Psychiatry.

[34]  K. Hsu,et al.  Rap1-induced p38 Mitogen-activated Protein Kinase Activation Facilitates AMPA Receptor Trafficking via the GDI·Rab5 Complex , 2004, Journal of Biological Chemistry.

[35]  K. Jellinger.  Huntington's Disease (3rd edn) , 2003 .

[36]  M. Geyer,et al.  The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity , 2002, Neuropharmacology.

[37]  P. Saggau,et al.  Modulation of Presynaptic Calcium Transients by Metabotropic Glutamate Receptor Activation: A Differential Role in Acute Depression of Synaptic Transmission and Long-Term Depression , 2002, The Journal of Neuroscience.

[38]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Nelson,et al.  Knockout mouse model for Fxr2: a model for mental retardation. , 2002, Human molecular genetics.

[40]  Darci M. Nielsen,et al.  Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome , 2002, Brain Research.

[41]  W. Spooren,et al.  Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain , 2001, Neuropharmacology.

[42]  J. Mandel,et al.  The Fragile X mental retardation protein , 2001, Brain Research Bulletin.

[43]  M. Koch,et al.  The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats , 2001, Neuropharmacology.

[44]  M. Bear,et al.  Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. , 2001, Journal of neurophysiology.

[45]  L. Chen,et al.  Fragile X mice develop sensory hyperreactivity to auditory stimuli , 2001, Neuroscience.

[46]  F. Gasparini,et al.  Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.

[47]  W. Spooren,et al.  Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. , 2000, The Journal of pharmacology and experimental therapeutics.

[48]  W. Spooren,et al.  Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. , 2000, European journal of pharmacology.

[49]  D. Nelson,et al.  (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. , 2000, Human molecular genetics.

[50]  Raffaele Ferri,et al.  Audiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome , 2000, Epilepsia.

[51]  R. Shigemoto,et al.  Chapter III Metabotropic glutamate receptors — immunocytochemical and in situ hybridization analyses , 2000 .

[52]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[53]  J. Roder,et al.  Mice Lacking Metabotropic Glutamate Receptor 5 Show Impaired Learning and Reduced CA1 Long-Term Potentiation (LTP) But Normal CA3 LTP , 1997, The Journal of Neuroscience.

[54]  R Lujan,et al.  Perisynaptic Location of Metabotropic Glutamate Receptors mGluR1 and mGluR5 on Dendrites and Dendritic Spines in the Rat Hippocampus , 1996, The European journal of neuroscience.

[55]  G. Collingridge,et al.  Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1 , 1994, Nature.

[56]  S. Tonegawa,et al.  Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice , 1994, Cell.

[57]  S. Tonegawa,et al.  Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice , 1994, Cell.

[58]  Guy Nagels,et al.  Fmr1 knockout mice: A model to study fragile X mental retardation , 1994, Cell.

[59]  R. D'Hooge,et al.  Fmr1 knockout mice: A model to study fragile X mental retardation , 1994, Cell.

[60]  G. Suthers.  Fragile X Syndrome—Diagnosis, Treatment, and Research , 1992 .

[61]  S. Handley,et al.  Effects of 5‐HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents , 1991, British journal of pharmacology.

[62]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[63]  Silverman,et al.  Fragile X Syndrome Diagnosis Treatment And Research , 2016 .

[64]  C. Broekkamp,et al.  Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. , 1986, European journal of pharmacology.

[65]  M. Alexander,et al.  Principles of Neural Science , 1981 .

[66]  H. Beecher,et al.  Human studies. , 1969, Science.